Advances and challenges in gene therapies (part 1)

15:00 • S6L1 • Challenges of AAV Gene Therapy Development for Duchenne Muscular Dystrophy > F. Francesco MUNTONI (London, Uk) 15:20 • S6L2 • The management of safety of gene therapy of neuromuscular diseases, an emblematic example > S. Serge BRAUN (Evry, France) 15:40 • S6L3 • The liver as a model tissue to develop innovative solutions to the existing limitations of AAV gene therapy > G. Giuseppe RONZITTI (Evry, France)